Long-term outcome of subretinal coapplication of rtPA and bevacizumab followed by repeated intravitreal anti-VEGF injections for neovascular AMD with submacular haemorrhage

British Journal of Ophthalmology

Volumn 96, Issue 5, 2012, Pages 708-713

  Treumer, Felix ^a   Roider, Johann ^a   Hillenkamp, Jost ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; BEVACIZUMAB; RANIBIZUMAB;

ADULT; AGED; ARTICLE; CASE STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTAMPONADE; FEMALE; HUMAN; INTERVENTION STUDY; MALE; PATIENT SAFETY; POSTOPERATIVE CARE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; READING; REPEATED DRUG DOSE; RETINA DETACHMENT; RETINA HEMORRHAGE; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA HOLE; RETINA NEOVASCULARIZATION; RETROSPECTIVE STUDY; SUBMACULAR HEMORRHAGE; THERAPY EFFECT; TREATMENT OUTCOME; VISUAL ACUITY; VITRECTOMY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DRUG THERAPY, COMBINATION; ENDOTAMPONADE; FEMALE; FIBRINOLYTIC AGENTS; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; RETINAL HEMORRHAGE; RETREATMENT; RETROSPECTIVE STUDIES; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITRECTOMY; WET MACULAR DEGENERATION;

EID: 84860215919     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2011-300655     Document Type: Article

References (22)

1. Avery RL, Fekrat S, Hawkins BS, et al. Natural history of subfoveal hemorrhage in age-related macular degeneration. Retina 1996;16:183-9. (Pubitemid 26190846)
2. Vander JF, Federman JL, Greven C, et al. Surgical removal of massive subretinal hemorrhage associated with age-related macular degeneration. Ophthalmology 1991;98:23-7.
3. Bressler NM, Bressler SB, Childs AL, et al; for Submacular Surgery Trials (SST) Research Group. Surgery for hemorrhagic choroidal neovascular lesions of age- related macular degeneration: ophthalmic findings: SST report No. 13. Ophthalmology 2004;111:1993-2006.
4. Lewis H. Intraoperative fibrinolysis of submacular hemorrhage with tissue plasminogen activator and surgical drainage. Am J Ophthalmol 1994;118:559-68. (Pubitemid 24345617)
5. Chen CY, Hooper C, Chiu D, et al. Management of submacular hemorrhage with intravitreal injection of tissue plasminogen activator and expansile gas. Retina 2007;27:321-8. (Pubitemid 46398897)
6. Hesse L, Schmidt J, Kroll P. Management of acute submacular hemorrhage using recombinant tissue plasminogen activator and gas. Graefes Arch Clin Exp Ophthalmol 1999;237:273-7. (Pubitemid 29145803)
7. Handwerger BA, Blodi BA, Chandra SR, et al. Treatment of submacular hemorrhage with low-dose intravitreal tissue plasminogen activator injection and pneumatic displacement. Arch Ophthalmol 2001;119:28-32. (Pubitemid 32096382)
8. Kamei M, Misono K, Lewis H. A study of the ability of tissue plasminogen activator to diffuse into the subretinal space after intravitreal injection in rabbits. Am J Ophthalmol 1999;128:739-46. (Pubitemid 30001770)
9. Takeuchi A, Kricorian G, Yao XY, et al. The rate and source of albumin entry into saline-filled experimental retinal detachments. Invest Ophthalmol Vis Sci 1994;35:3792-8. (Pubitemid 24334536)
10. Jackson TL, Antcliff RJ, Hillenkamp J, et al. Human retinal molecular weight exclusion limit and estimate of species variation. Invest Ophthalmol Vis Sci 2003;44:2141-6. (Pubitemid 36520310)
11. Heiduschka P, Fietz H, Hofmeister S, et al Tübingen Bevacizumab Study Group. Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci 2007;48:2814-23. (Pubitemid 351261238)
12. Haupert CL, McCuen BW 2nd, Jaffe GJ. Pars plana vitrectomy, subretinal injection of tissue plasminogen activator, and fluid-gas exchange for displacement of thick submacular hemorrhage in age-related macular degeneration. Am J Ophthalmol 2001;131:208-15. (Pubitemid 32157035)
13. Olivier S, Chow DR, Packo KH. Subretinal recombinant tissue plasminogen activator injection and pneumatic displacement of thick submacular hemorrhage in age-related macular degeneration. Ophthalmology 2004;111:1201-8. (Pubitemid 38737001)
14. Hillenkamp J, Surguch V, Framme C, et al. Management of submacular hemorrhage with intravitreal versus subretinal injection of recombinant tissue plasminogen activator. Graefes Arch Clin Exp Ophthalmol 2010;248:5-11.
15. Treumer F, Klatt C, Roider J, et al. Subretinal co-application of recombinant tissue plasminogen activator and bevacizumab for neovascular age-related macular degeneration with submacular hemorrhage. Br J Ophthalmol 2010;94:48-53.
16. Schouten JS, La Heij EC, Webers CA, et al. A systematic review on the effect of bevacizumab in exudative age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2009;247:1-11.
17. Heimes B, Lommatzsch A, Zeimer M, et al. Long-term visual course after anti-VEGF therapy for exudative AMD in clinical practice evaluation of the German reinjection scheme. Graefes Arch Clin Exp Ophthalmol 2011;249:639-44.
18. Meyer CH, Scholl HP, Eter N, et al. Combined treatment of acute subretinal haemorrhages with intravitreal recombined tissue plasminogen activator, expansile gas and bevacizumab: a retrospective pilot study. Acta Ophthalmol 2008;86:490-4.
19. Ohji M, Saito Y, Hayashi A, et al. Pneumatic displacement of subretinal hemorrhage without tissue plasminogen activator. Arch Ophthalmol 1998;116:1326-32. (Pubitemid 28473837)
20. Dadgostar H, Ventura AA, Chung JY, et al. Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration. Ophthalmology 2009;116:1740-7.
21. Gerding H, Loukopoulos V, Riese J, et al. Results of flexible ranibizumab treatment in age-related macular degeneration and search for parameters with impact on outcome. Graefes Arch Clin Exp Ophthalmol 2011;249:653-62.
22. Pauleikhoff D, Kirchhof B. Retreatment criteria in anti-VEGF therapy of exudative AMD: critical analysis of present regimes and new morphological definition of "lesion activity". Graefes Arch Clin Exp Ophthalmol 2011;249:631-2.